The Challenges of Identifying Biomarkers in Lung Cancer

July 18, 2014
Edward S. Kim, MD

Edward S. Kim, MD, chairman, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, discusses some of the challenges researchers face when it comes to biomarkers in lung cancer.

Edward S. Kim, MD, chairman, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, discusses some of the challenges researchers face when it comes to biomarkers in lung cancer.

Clinical Pearls:

  • Research presented at the 2014 ASCO Annual Meeting highlighted many different techniques and markers in the field of lung cancer.
  • Because there are so many targeted therapies that are being developed, researchers are searching for the right biomarker in the patient to match with the targeted therapy.
  • Only about 20% of lung cancer patients are covered with a biomarker that has a corresponding therapy.​